Effect of MAO‐A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans

Abstract

Moclobemide increased plasma concentrations of almotriptan on average by 37%, but the combined administration of these two compounds was well tolerated. The degree of interaction was much less than that seen previously for sumatriptan or zolmitriptan given with moclobemide.